TY - JOUR
T1 - Association between Visual Field Damage and Gait Dysfunction in Patients with Glaucoma
AU - Jian-Yu, E.
AU - Mihailovic, Aleksandra
AU - Garzon, Catalina
AU - Schrack, Jennifer A.
AU - Li, Tianjing
AU - West, Sheila K.
AU - Gitlin, Laura N.
AU - Friedman, David S.
AU - Ramulu, Pradeep Y.
N1 - Funding Information:
Funding/Support: The research was supported in part by the National Institutes of Health (grant EY022976).
Funding Information:
reported grants from the National Eye Institute during the conduct of the study. Dr Schrack reported grants from the National Institute on Aging during the conduct of the study. Dr Ramulu reported grants from the National Institutes of Health during the conduct of the study. No other disclosures were reported.
Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/10
Y1 - 2021/10
N2 - Importance: Gait dysfunction is common in older people with visual impairment and is a major cause of falls. Objective: To compare 3-year longitudinal changes in gait measures across the spectrum of baseline visual field (VF) damage in glaucoma. Design, Setting, and Participants: A post hoc analysis was designed on September 1, 2018, following a prospective cohort study, which enrolled older adults with glaucoma or suspected glaucoma from September 2013 to March 2015 and followed up for up to 3 years. Baseline VF damage was defined by integrated VF (IVF) sensitivity and categorized as normal/mild (IVF >28 dB), moderate (IVF, 23-28 dB), and severe (IVF, <23 dB). Each participant walked on an electronic walkway back and forth twice at normal pace each study year. Linear mixed-effects models evaluated longitudinal change in gait outcomes (1) stratified within each VF severity category and (2) across the range of IVF sensitivity. Analysis took place from October 2019 to October 2020. Main Outcomes and Measures: Three-year changes in 7 gait assessments under usual-pace walking, including base support and its coefficient of variation, stride length and its coefficient of variation, stride velocity and its coefficient of variation, and cadence. Results: Of 241 participants, the mean (SD) age was 70.8 (7.7) years, 116 (48.2%) were women, and 70 (29.0%) were African American. When comparing longitudinal gait changes over 3 years across the spectrum of IVF sensitivity, each 5-unit (dB) decrement was associated with more rapid declines in stride velocity (-0.05 z score unit/y; 95% CI, -0.09 to -0.01; P =.01) and cadence (-0.07 z score unit/y; 95% CI, -0.10 to -0.03; P <.001). When evaluating gait changes within each glaucoma severity group, shorter stride length was associated with persons with normal/mild (-0.06 z score unit/y; 95% CI, -0.10 to -0.03; P =.001), moderate (-0.08 z score unit/y; 95% CI, -0.12 to -0.04; P <.001), and severe VF damage (-0.16 z score unit/y; 95% CI, -0.24 to -0.07; P <.001), while stride velocity (-0.18 z score unit; 95% CI, -0.28 to -0.07; P =.002) and slower cadence (-0.15 z score unit; 95% CI, -0.25 to -0.04; P =.006) were associated with those with severe VF damage. Conclusions and Relevance: At worse levels of baseline VF damage, patients with glaucoma in this study demonstrated an exacerbated decline in walking speeds (ie, stride velocity and cadence), indicating that mobility speeds decrease faster over time in older adults with glaucoma..
AB - Importance: Gait dysfunction is common in older people with visual impairment and is a major cause of falls. Objective: To compare 3-year longitudinal changes in gait measures across the spectrum of baseline visual field (VF) damage in glaucoma. Design, Setting, and Participants: A post hoc analysis was designed on September 1, 2018, following a prospective cohort study, which enrolled older adults with glaucoma or suspected glaucoma from September 2013 to March 2015 and followed up for up to 3 years. Baseline VF damage was defined by integrated VF (IVF) sensitivity and categorized as normal/mild (IVF >28 dB), moderate (IVF, 23-28 dB), and severe (IVF, <23 dB). Each participant walked on an electronic walkway back and forth twice at normal pace each study year. Linear mixed-effects models evaluated longitudinal change in gait outcomes (1) stratified within each VF severity category and (2) across the range of IVF sensitivity. Analysis took place from October 2019 to October 2020. Main Outcomes and Measures: Three-year changes in 7 gait assessments under usual-pace walking, including base support and its coefficient of variation, stride length and its coefficient of variation, stride velocity and its coefficient of variation, and cadence. Results: Of 241 participants, the mean (SD) age was 70.8 (7.7) years, 116 (48.2%) were women, and 70 (29.0%) were African American. When comparing longitudinal gait changes over 3 years across the spectrum of IVF sensitivity, each 5-unit (dB) decrement was associated with more rapid declines in stride velocity (-0.05 z score unit/y; 95% CI, -0.09 to -0.01; P =.01) and cadence (-0.07 z score unit/y; 95% CI, -0.10 to -0.03; P <.001). When evaluating gait changes within each glaucoma severity group, shorter stride length was associated with persons with normal/mild (-0.06 z score unit/y; 95% CI, -0.10 to -0.03; P =.001), moderate (-0.08 z score unit/y; 95% CI, -0.12 to -0.04; P <.001), and severe VF damage (-0.16 z score unit/y; 95% CI, -0.24 to -0.07; P <.001), while stride velocity (-0.18 z score unit; 95% CI, -0.28 to -0.07; P =.002) and slower cadence (-0.15 z score unit; 95% CI, -0.25 to -0.04; P =.006) were associated with those with severe VF damage. Conclusions and Relevance: At worse levels of baseline VF damage, patients with glaucoma in this study demonstrated an exacerbated decline in walking speeds (ie, stride velocity and cadence), indicating that mobility speeds decrease faster over time in older adults with glaucoma..
UR - http://www.scopus.com/inward/record.url?scp=85111402006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111402006&partnerID=8YFLogxK
U2 - 10.1001/jamaophthalmol.2021.2617
DO - 10.1001/jamaophthalmol.2021.2617
M3 - Article
C2 - 34292297
AN - SCOPUS:85111402006
SN - 2168-6165
VL - 139
SP - 1053
EP - 1060
JO - JAMA Ophthalmology
JF - JAMA Ophthalmology
IS - 10
ER -